EvoBiotech is a Biotech company developing a novel technology platform using plant-derived Extracellular Vesicles (EV) aimed at improving the healing efficacy of advanced dressings and medications used in wound care treatments and at developing a new drug delivery system, thanks to the natural carrier ability and resistance to degradation of plant-derived EV loaded with mRNA, nucleic acids, small molecules, and drugs. This technique offers significant clinical advantages such as a particularly easy way of administration (enteral, parenteral, and intranasal routes) and a high safety profile thanks to their natural origin. Advantages that can be easily used as a market opportunity due to the limited costs for scaling up production and distribution.

Marco Dieci, post-graduate degree in Chemistry, brings over 25 years of management experience in the life science industry, specifically in clinical operations management, pharma business development, and market access. He served as CEO at Holostem, Executive Director at the facility of Children Hospital Bambino Gesù in Rome, CEO of Xellbiogene, and Operations Director at MolMed.

The appointment of Marco Dieci as a member of the Board and COO represents a planned step in the consolidation of the Company’s clinical and industrial development.

“We are really pleased to bring Marco Dieci in our Board of Directors and have his support as COO” said Prof. Giovanni Camussi - Founder and Chairman of EvoBiotech. “Thanks to his broad professional experience, Marco will apply his know-how for improving clinical development and market access of our products. He will provide effective leadership and management support, guiding the Company to successful interactions with industry players. We are confident that Marco will positively contribute to the industrial development of EvoBiotech, and he will lead the Team toward our next goals”.

“Extracellular Vesicles (EV) derived from edible plants represent a breakthrough innovation suitable for several applications, such as drug delivery, regenerative medicine, and several additional applications. Thanks to the edible plant origin of the EV, this technique’s costs of production and distribution are significantly low. I am particularly excited to initiate this collaboration with this talented Team and to contribute to the development of a variety of products from bench to bed for patients' benefit”, commented Mr. Marco Dieci.

About EvoBiotech: EvoBiotech is based in Turin, Italy, and is developing a new generation of innovative therapies for wound care and drug delivery. The technology platform uses the power and the numerous advantages of plant-derived extracellular vesicles for improving the efficacy of current wound care treatments and drug delivery systems. Thanks to this approach, EvoBiotech aims to match the latest scientific discoveries with patients' and healthcare professionals' needs in wound care and drug delivery fields.